---
title: "Soligenix, Inc. (SNGX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/SNGX.US.md"
symbol: "SNGX.US"
name: "Soligenix, Inc."
industry: "Biotechnology"
datetime: "2026-03-15T18:51:09.957Z"
locales:
  - [en](https://longbridge.com/en/quote/SNGX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/SNGX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/SNGX.US.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/SNGX.US.md) | [繁體中文](https://longbridge.com/zh-HK/quote/SNGX.US.md)


# Soligenix, Inc. (SNGX.US)

## Company Overview

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. It operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in Phase 3 clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX945, an IDR technology that is in Phase 2a study to treat aphthous ulcers in Behçet’s disease; and SGX302, an IDR technology, which is in Phase 2a study for the treatment of mild-to-moderate psoriasis. Its Public Health Solutions segment engages in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a, 1b, and 1c clinical trials; SGX943, a therapeutic candidate in preclinical studies for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; CiVax, a vaccine candidate for the prevention of COVID-19; and vaccine programs that target filoviruses, such as Marburg and Ebola.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.soligenix.com](https://www.soligenix.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-03-15T04:30:13.000Z

**Overall: D (0.75)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 311 / 402 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -100.00% |  |
| Net Profit YoY | -57.37% |  |
| P/B Ratio | 1.63 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 12405939.90 |  |
| Revenue | 0.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -165.10% | E |
| Profit Margin | 0.00% | D |
| Gross Margin | 0.00% | E |
| Revenue YoY | -100.00% | E |
| Net Profit YoY | -57.37% | D |
| Total Assets YoY | 7.80% | B |
| Net Assets YoY | 28.02% | A |
| Cash Flow Margin | 0.00% | D |
| OCF YoY | -100.00% | E |
| Turnover | 0.00 | E |
| Gearing Ratio | 32.73% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Soligenix, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-100.00%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-57.37%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.63",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "12405939.90",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "0.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-165.10%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "0.00%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "-100.00%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-57.37%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "7.80%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "28.02%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-100.00%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "32.73%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.11 | 200/402 | - | - | - |
| PB | 1.63 | 148/402 | 3.84 | 1.73 | 1.49 |
| PS (TTM) | 4097.86 | - | 4097.86 | 4097.86 | 1825.92 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Stoke Therapeutics (STOK.US) | A | A | B | A | B | A |
| 03 | MiMedx (MDXG.US) | A | B | A | B | B | A |
| 04 | Rigel Pharma (RIGL.US) | A | A | B | B | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-03-12T04:00:00.000Z

Total Analysts: **2**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 50% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 1.23 |
| Highest Target | 25.00 |
| Lowest Target | 10.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/SNGX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/SNGX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/SNGX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/SNGX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**